Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics today announced that they have signed a PER.C6® research license agreement with the Taiwan-based AbGenomics Corporation.
AbGenomics Corporation intends to use the PER.C6® cell line for its research, development and early clinical studies of monoclonal antibodies.

"The unique characteristics of the PER.C6® technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology's robustness undoubtedly makes our choice for PER.C6® highly imperative," said Shih-Yao Lin, PhD, AbGenomics Corporation's President.

Under the terms of this agreement, AbGenomics Corporation will make license payments and annual maintenance fees in exchange for certain rights. Further financial details were not disclosed.

About AbGenomics Corporation
AbGenomics Corporation is a biotechnology company focused on the discovery and development of breakthrough medicines to treat serious life threatening and debilitating diseases, including cancer, inflammations, autoimmune, infectious and metabolic diseases. The Company's business strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. For more information, please visit www.abgenomics.com